Clinical Trials
2 trialsNCT05495828 2023-10-26
Orelabrutinib Therapy in Patients With r/r B-cell Lymphoma Intolerant to Other Bruton Tyrosine Kinase Inhibitors
Peking University People's Hospital
Unknown
NCT06015464 2023-08-29
An Ambispective Cohort Study of Orelabrutinib in Combination With Standard Treatment Regimen for Untreated DLBCL
The First Affiliated Hospital with Nanjing Medical University
Unknown